Drug profile · INN
infliximab-abda
RENFLEXIS
infliximab-abda (RENFLEXIS) is a tnf-alpha inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — infliximab-abda
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
infliximab-abda (RENFLEXIS) is a tnf-alpha inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
TNF-alpha inhibitor
Primary target: Tumor necrosis factor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is infliximab-abda?
infliximab-abda (RENFLEXIS) is a tnf-alpha inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for infliximab-abda?
RENFLEXIS is a marketed brand name for infliximab-abda. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of infliximab-abda?
infliximab-abda has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.